Page 354 - Read Online

Krastev et al. Hepatoma Res 2019;5:35 Hepatoma Research
DOI: 10.20517/2394-5079.2019.02

Case Report Open Access

Hepatocellular carcinoma in HCV - liver cirrhosis
before and after successful DAA treatment

Zahari Krastev , Deian Jelev , Donika Krasteva , Jordan Genov , Teodora Komitova 2
1
1
1
2
1 Clinic of Gastroenterology, University Hospital Sv. Ivan Rilski, Medical University, Sofia 1431, Bulgaria.
2 Clinic of Gastroenterology, University Hospital Tsaritsa Yoanna - ISUL, Medical University, Sofia 1527, Bulgaria.
Correspondence to: Dr. Donika Krasteva, Clinic of Gastroenterology, University Hospital Sv. Ivan Rilski, Medical University, Sofia 1431,
Bulgaria. E-mail: donika.krysteva@gmail.com

How to cite this article: Krastev Z, Jelev D, Krasteva D, Genov J, Komitova T. Hepatocellular carcinoma in HCV - liver cirrhosis before
and after successful DAA treatment. Hepatoma Res 2019;5:35. http://dx.doi.org/10.20517/2394-5079.2019.02

Received: 24 Jun 2019 First Decision: 5 Aug 2019 Revised: 29 Aug 2019 Accepted: 3 Sep 2019 Published: 13 Oct 2019

Science Editor: Guangwen Cao Copy Editor: Jia-Jia Meng Production Editor: Tian Zhang

Abstract
Chronic hepatitis C virus (HCV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma (HCC)
worldwide. The recent advancement of direct-acting Antiviral Agents (DAAs) in hepatitis C therapy, resulted
in sustained virological response rates of over 90% in treated patients in different stages of liver fibrosis. The
efficacy of DAAs treatment has also been confirmed in real-life cohorts that include subjects with decompensated
cirrhosis and therefore seems a promising step to a significant reduction in the recurrence of HCC in patients who
achieved complete destruction of the HCC nodules by local therapy. We present a 72-year old patient with HCV-
related liver cirrhosis who successfully responded to DAAs treatment after complete destruction of an early HCC
nodule.

Keywords: Hepatocellular carcinoma, hepatitis C virus infection, Direct-acting Antiviral Agents, hepatocellular
carcinoma recurrence

INTRODUCTION
The clinical implementation of direct-acting Antiviral Agents (DAAs) therapy allowed achieving over 90%
sustained virological response (SVR) rate in treated patients with chronic hepatitis C virus (HCV) infection
[1-3]
regardless of the presence of liver cirrhosis . The efficacy of DAAs treatment has also been confirmed in
real-life cohorts that include subjects with decompensated cirrhosis and therefore seems a promising step

© The Author(s) 2019. Open Access This article is licensed under a Creative Commons Attribution 4.0
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long
as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license,
and indicate if changes were made.

www.hrjournal.net